Publication Cover
AIDS Care
Psychological and Socio-medical Aspects of AIDS/HIV
Volume 26, 2014 - Issue 4
254
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden

, , , , , , & show all
Pages 466-475 | Received 13 Sep 2012, Accepted 04 Sep 2013, Published online: 10 Oct 2013
 

Abstract

While the burden of HIV disease is well documented, the value of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy regimens in reducing patient burden is not well understood. The purpose of this study was to examine patient-reported health among those receiving NNRTI-based regimens to understand their incremental value in reducing the burden of HIV. We conducted a structured literature review using PubMed to identify NNRTI trials utilizing validated patient-reported outcome (PRO) instruments during 2005–2011. The search strategy included a PubMed search to identify relevant studies based on disease, instrument, PRO, and NNRTI medication terms; and a manual search of bibliographies of identified papers. Data abstracted from each study included study type, treatment regimen(s), and PRO results. Of 11 trials identified, 8 (73%) reported significance of changes in a PRO over time and 10 (91%) reported significance of PRO changes between groups. Several domains were assessed, with significant findings (between or within groups) observed in: physical health/well-being (n = 5), emotional status/well-being (n = 2), symptoms (n = 2), anxiety (n = 2), gastrointestinal upset (n = 2), psychological health (n = 1), functional and global well-being (n = 1), fatigue/energy (n = 1), depression (n = 1), change in body appearance (n = 1), pain (n = 1), headache (n = 1), bad dreams/nightmares (n = 1), problems having sex (n = 1), and general health perception (n = 1). In conclusion, NNRTIs have been observed most frequently to improve patient-reported physical health and well-being. Treatments are needed that can also reduce patient burden in areas of emotional well-being, cognitive functioning, and overall symptom profile.

Acknowledgments

Kristin A. Hanson and Chris L. Pashos are employees of UBC: An Express Scripts Company and Gale Harding is an employee of Evidera, both of which received funding for this research from Pfizer. Seema Haider and Margaret Tawadrous are employees of and have equity ownership in Pfizer. Alexandra Khachatryan was an employee of Pfizer at the time the study was conducted. Kit N. Simpson and Albert W. Wu received funding for this research from Pfizer.

Supplemental Material

All Supplemental Material is available alongside this article on www.tandfonline.com – go to http://dx.doi.org/10.1080/09540121.2013.841825

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 53.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 464.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.